SEB Asset Management AB Acquires Shares of 46,343 Krystal Biotech, Inc. $KRYS

SEB Asset Management AB purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 46,343 shares of the company’s stock, valued at approximately $11,971,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KRYS. UMB Bank n.a. lifted its stake in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the last quarter. Optimize Financial Inc boosted its holdings in Krystal Biotech by 1.4% in the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after acquiring an additional 40 shares during the last quarter. Perigon Wealth Management LLC increased its position in shares of Krystal Biotech by 0.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after buying an additional 41 shares during the period. Regal Investment Advisors LLC raised its position in shares of Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after acquiring an additional 44 shares in the last quarter. Finally, Torray Investment Partners LLC lifted its stake in Krystal Biotech by 0.4% in the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after buying an additional 47 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $339.22 on Tuesday. The firm has a market capitalization of $10.00 billion, a P/E ratio of 45.35 and a beta of 0.50. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $382.54. The company’s 50-day simple moving average is $331.91 and its 200 day simple moving average is $290.37.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities research analysts expect that Krystal Biotech, Inc. will post 7.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last ninety days. 13.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. HC Wainwright upped their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Bank of America raised their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. TD Cowen raised their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.